Glucagon like peptide-1

PreclinicalPeptide

UUniversity Hospital, Gentofte, Copenhagen

Glucagon like peptide-1 is one of 36 small molecule programs targeting Angioedema. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AngioedemaActive, not recruiting

HypoglycemiaActive, not recruiting

HeartCompleted

AngioedemaPreclinical

Active, not recruiting

HypoglycemiaPreclinical

Active, not recruiting

HeartPreclinical

Completed

Competition

Competitive Landscape

26 competitors in Hypoglycemia

#DrugCompanyPhaseTrials

NOVOLIN R

Novo Nordisk

Approved

1 2

Aldactone

Pfizer

Approved

1 3

Avelox

Narcan

2 5

Proglycem

Teva

Approved

1 6

Symlin

AstraZeneca

Approved

1 7

Januvia

ZZydus Therapeutics Inc.

Approved

1 8

Luxiq

SSchering-Plough

Approved

1 9

Reglan

IIstituto Clinico Humanitas

Phase 2

1 10

Avexitide

AAmylyx Pharmaceuticals Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

GLP-12 trials

Near Normalisation of BG Improves the Potentiating Effect of GLP-1

Completed·HHvidovre University Hospital·N/A·NCT00612625·9 enrolled

Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates

Terminated·—·Phase 1/2·NCT00609154·20 enrolled

Angioedema1 trial

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Completed·VVanderbilt University·N/A·NCT01413542·44 enrolled

Beta-cell Function1 trial

Beta-Cell Function After Near-Normalisation of Blood Glucose

Completed·HHvidovre University Hospital·N/A·NCT00612950·8 enrolled

Type 2 Diabetes1 trial

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet recruiting·—·Phase 4·NCT06449235·938 enrolled

Critically Ill Patients1 trial

The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

Terminated·JJohns Hopkins University·Phase 2·NCT00798590·19 enrolled

9 more indications

Pancreatic1 trial

Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism

Unknown status·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT02944110·20 enrolled

Inflammation1 trial

The Differential Effects of Diabetes Therapy on Inflammation

Completed·UUniversity College Dublin··NCT02150707·17 enrolled

Heart1 trial

The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men

Completed·UUniversity of Aarhus·N/A·NCT00256256·10 enrolled

Hypoglycemia1 trial

The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia

Completed·UUniversity of Aarhus·N/A·NCT00418288·10 enrolled

Heart Failure1 trial

The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure

Completed·PPapworth Hospital NHS Foundation Trust·Phase 1·NCT02129179·10 enrolled

Type 2 Diabetes Mellitus1 trial

Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus

Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT00923962·35 enrolled

Type 1 Diabetes1 trial

Glucagon-like Peptide-1 in Type 1 Diabetes

Withdrawn·UUniversity of Maryland, Baltimore·Phase 1·NCT04355832

Diabetes1 trial

The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea

Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT03081676·20 enrolled

Hemodynamic1 trial

Acute Effects of GLP-1 on Renal Hemodynamics

Completed·RRigshospitalet, Denmark·N/A·NCT04337268·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Glucagon like peptide-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glucagon like peptide-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glucagon like peptide-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Gentofte, Copenhagen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Gentofte, Copenhagen

Glucagon like peptide-1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

GLP-12 trials

Angioedema1 trial

Beta-cell Function1 trial

Type 2 Diabetes1 trial

Critically Ill Patients1 trial

Pancreatic1 trial

Inflammation1 trial

Heart1 trial

Hypoglycemia1 trial

Heart Failure1 trial

Type 2 Diabetes Mellitus1 trial

Type 1 Diabetes1 trial

Diabetes1 trial

Hemodynamic1 trial

References

Drug Info

Quick Facts

Related News